Kymera Therapeutics

C4 Therapeutics

This biopharmaceutical company develops small-molecule medicines that degrade disease-causing proteins to treat cancer and other difficult diseases for patients and healthcare providers.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Frontier Medicines

This biopharmaceutical company develops small-molecule precision medicines targeting undruggable proteins for patients with cancer and immunological diseases.

Sibylla Biotech

This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.

Ligature Therapeutics

This biotech company develops protein degrader therapeutics using a fragment-based discovery platform to treat intractable diseases for patients with cancer.